Redeye leaves a comment on the Q3 report published by Lipum earlier this morning. A quarter marked by the historical initiation of the first clinical trial with the company’s lead candidate, SOL-116.
ANNONS
Redeye leaves a comment on the Q3 report published by Lipum earlier this morning. A quarter marked by the historical initiation of the first clinical trial with the company’s lead candidate, SOL-116.